Novo Nordisk sues spas and clinics for selling versions of Wegovy and Ozempic for weight loss

In the latest fracas over obesity drugs, Novo Nordisk filed lawsuits alleging several medical spas, wellness clinics, and weight loss clinics around the U.S. are illegally selling compounded versions of its medicines.

The drugmaker accused the businesses of false advertising, unfair competition, and infringing on trademarks for three medicines: Wegovy, Ozempic, and Rybelsus. All three drugs are used to treat diabetes, although Wegovy was also approved by U.S. regulators to help people with overweight or obesity lose weight if they have a related condition such as high blood pressure.

All three drugs contain the same active ingredient, known as semaglutide. Use of semaglutide has soared amid a tremendous amount of interest in the drugs, some spurred by social media and celebrity use. Unlike earlier rounds of prescription diet pills, medicines containing semaglutide do not produce the same troubling side effects.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In